Virax Biolabs Director Departs
Ticker: VRAX · Form: 6-K · Filed: Jun 11, 2024 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, corporate-governance
TL;DR
Virax Biolabs director Nigel James has stepped down as of June 11, 2024.
AI Summary
Virax Biolabs Group Ltd. announced the departure of Nigel James, a director, effective June 11, 2024. The company, which is incorporated in the United Kingdom and focuses on in vitro and in vivo diagnostic substances, filed this Form 6-K to report this change. The principal executive offices are located in Lanarkshire, United Kingdom.
Why It Matters
Director changes can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing solely reports a director's departure, which is a routine corporate event with no immediate financial implications.
Key Players & Entities
- Virax Biolabs Group Ltd (company) — Registrant
- Nigel James (person) — Departing Director
- June 11, 2024 (date) — Effective date of director's departure
- 001-41440 (other) — SEC File Number
FAQ
Who is Nigel James and what was his role at Virax Biolabs Group Ltd?
Nigel James was a director of Virax Biolabs Group Ltd.
When did Nigel James's departure become effective?
Nigel James's departure was effective as of June 11, 2024.
What type of company is Virax Biolabs Group Ltd?
Virax Biolabs Group Ltd. is a foreign private issuer focused on in vitro & in vivo diagnostic substances.
What is the SEC file number for Virax Biolabs Group Ltd?
The SEC file number for Virax Biolabs Group Ltd. is 001-41440.
What is the principal executive office address for Virax Biolabs Group Ltd?
The principal executive office is located at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-11 16:30:02
Filing Documents
- 6-k_director_change_nige.htm (6-K) — 24KB
- 0000950170-24-071955.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: June 11, 2024 By: /s/ James Foster James Foster, Chief Executive Officer